Physician profile
Howard Eisenberg
NPI 1053312835
$4,988.09
in general payments reported to CMS, 2019-2025
29 companies · $702 in 2025
The $702 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $383 · 2021: $691 · 2022: $879 · 2023: $909 · 2024: $503 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.20 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,307.91 | 2019-2025 | |
| Organon LLC | $436.29 | 2021-2025 | Nexplanon, Nuvaring |
| Astellas Pharma US INC | $356.27 | 2019-2025 | Veozah, Myrbetriq |
| Biogen, INC. | $346.37 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $341.96 | 2019-2025 | Gardasil 9, Gardasil |
| Hologic Sales and Service, LLC | $282.05 | 2019-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $252.22 | 2019-2023 | |
| Myovant Sciences INC. | $250.80 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $223.47 | 2023-2024 | Myfembree |
| Mayne Pharma Commercial LLC | $212.15 | 2023-2024 | |
| Exeltis, USA INC. | $135.14 | 2020-2023 | Slynd |
| Pfizer INC. | $119.82 | 2019-2025 | |
| Therapeuticsmd, INC. | $95.00 | 2020-2022 | |
| Aspira Women'S Health INC | $68.88 | 2020-2024 | Ova1 |
| Coopersurgical, INC. | $68.82 | 2019-2025 | Paragard T 380a |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $59.32 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $58.33 | 2019 | |
| Millicent US INC | $57.03 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Myriad Women'S Health, INC. | $47.75 | 2023 | Myrisk |
| Daiichi Sankyo INC. | $47.52 | 2021 | |
| Becton, Dickinson and Company | $42.55 | 2022-2024 | Bd Onclarity |
| Boston Scientific Corporation | $32.70 | 2024 | Upsylon, Solyx Sis System |
| Gynesonics, INC. | $32.47 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Medtronic, INC. | $27.21 | 2024 | Ligasure |
| Evofem Biosciences, INC. | $25.93 | 2020-2021 | |
| Dexcom, INC. | $16.54 | 2023 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $16.09 | 2021 | |
| Agile Therapeutics, INC. | $14.27 | 2024 | Twirla |
| Caldera Medical, INC | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Eisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.